Ibufen

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ibufen

Property Description
Active Ingredient Ibuprofen (Isobutylphenyl propionic acid)
Forms Tablet, Capsule, Liquid Gel, Oral Suspension, Suppository
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose Analgesic, Anti-inflammatory, Antipyretic
Origin Synthetic Compound

Ibufen is a medicinal product whose active component is Ibuprofen, a substance classified pharmacologically as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This product is a synthetic compound derived from propionic acid, positioning it as a foundational medicine for addressing acute physical discomfort. Ibuprofen is supported by extensive pharmacological studies and is widely utilized in clinical practice. As a single-ingredient product, Ibufen's identity is defined entirely by the established properties of its core chemical entity, isobutylphenyl propionic acid.


What Type of Medicine is Ibufen (Ibuprofen)?

Ibufen belongs to the Nonsteroidal Anti-Inflammatory Drug (NSAID) class, a category of substances primarily recognized for their capability to reduce inflammation and relieve pain. Ibuprofen is utilized to relieve symptoms such as pain, fever, and inflammation. The active ingredient, Ibuprofen, acts by intervening directly in the biochemical processes of inflammation by inhibiting the production of prostaglandins, the chemical mediators responsible for generating pain and fever. The NSAID classification signifies that the substance targets the underlying chemical cause of the symptoms rather than just altering the central perception of pain.


What are the Common Forms and General Purpose of Ibufen?

Ibufen is manufactured for systemic administration and is available in various dosage forms, including the common tablet, capsule, liquid gel, oral suspension, and suppository. The inclusion of the oral suspension form facilitates administration to the pediatric patient group, a key differentiating feature. The general therapeutic purpose of Ibufen is to provide concurrent analgesic (pain relief), anti-inflammatory, and antipyretic (fever reduction) relief. By delivering the Ibuprofen compound via these oral and rectal routes, the medicine is absorbed into the bloodstream, where it acts systemically to address generalized pain, inflammation, and elevated body temperature often associated with common inflammatory episodes.

Regulatory References

  1. WHO Essential Medicines List
  2. NIH National Library of Medicine

What side effects are possible with Ibufen?

Possible Side Effects and Safety Information

The safety profile of Ibufen is structured around officially documented adverse reactions and specific regulatory warnings, generally requiring the use of the lowest effective dose for the shortest duration necessary.

Serious Adverse Reactions

Governmental regulatory authorities highlight the risk of serious, potentially fatal events:

  • Cardiovascular Thrombotic Events: The medicine carries a documented risk of potentially fatal heart attack (myocardial infarction) and stroke, which may increase with higher doses and longer duration of use.
  • Gastrointestinal Events: Serious gastrointestinal adverse reactions include bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Risk increases with dose and duration.
  • Hypersensitivity and Skin Reactions: Severe, sometimes fatal, skin reactions (e.g., Stevens-Johnson Syndrome) and acute hypersensitivity reactions (e.g., anaphylaxis) are documented.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by how often they occur, according to official regulatory systems:

Classification Examples of Reactions (System-Organ Class)
Common Nausea, vomiting, indigestion, constipation, flatulence (Gastrointestinal); headache (Nervous System)
Uncommon Peptic ulcers, gastritis (Gastrointestinal); insomnia, anxiety (Nervous System); rash, pruritus (Skin)
Rare/Very Rare Aseptic meningitis (Nervous System); acute renal failure (Renal); severe cardiac failure, hypertension (Cardiac/Vascular); hepatitis (Hepato-biliary)

Safety-Related Restrictions

Ibufen is officially contraindicated (should not be used) in certain circumstances based on regulatory documents:

  • Patients who have experienced allergic reactions (e.g., asthma, hives) to aspirin or other NSAIDs.
  • Patients with active or recurrent peptic ulcer disease or gastrointestinal bleeding.
  • Use in the setting of coronary artery bypass graft (CABG) surgery.
  • Use during the third trimester of pregnancy.
  • Patients with severe heart, kidney, or liver failure.

Overdose and Emergency Response

The official regulatory profile for Ibufen (Ibuprofen) overdose defines the presentation by its potential effects across key physiological systems.

Overdose Scope

Documented overdose presentations:

  • Gastrointestinal effects including abdominal pain, nausea, vomiting, and diarrhea.
  • Central Nervous System (CNS) disturbances such as drowsiness, confusion, severe headache, and the potential for convulsions.
  • Systemic effects like low blood pressure (hypotension), irregular heartbeat, and respiratory depression.

Population-specific overdose notes (if applicable):

  • Elderly patients are documented as having an increased risk for serious gastrointestinal complications, including bleeding and perforation, in overdose scenarios.

Emergency-response statements (as written in official documents):

  • Management is strictly symptomatic treatment and supportive care, as no specific antidote is known for Ibuprofen overdose.
  • Authorities mandate that immediate medical attention must be sought, and a Poison Control Center contacted for any suspected overdose, even if initial symptoms are absent.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents):

  • Overdose severity ranges up to life-threatening outcomes such as metabolic acidosis, acute kidney failure, and coma.

Resulting Overdose Structure

Official overdose statements:

  • Severe outcomes include acute kidney failure and severe gastrointestinal bleeding.
  • Monitoring of vital signs and a period of hospital observation are required elements of supportive management.
  • Prompt medical attention is critical for reducing the risk of severe systemic and organ toxicity.

Therapeutic Uses of Ibufen

Ibufen is commonly used to provide symptomatic relief across key domains where additional symptomatic support is needed. The therapeutic role of Ibufen is established in the management of these key symptom domains, including easing acute discomfort, inflammation, and systemic imbalance. The medication generally assists with maintaining functional stability and contributes to easing the overall symptom burden during difficult episodes.


Key Areas of Symptom Management

Ibufen is applied across domains where short-term symptom management is appropriate, notably for the sudden onset of headache, toothache, and general muscular aches. It is also relevant in supportive care for chronic conditions involving inflammatory processes like osteoarthritis and rheumatoid arthritis, and is used for managing the episodic discomfort of primary dysmenorrhea (menstrual cramping).

This focus on multifaceted relief is relevant for easing symptom clusters that may become intense or disruptive, such as the concurrence of pain, swelling, stiffness, and fever, which can create noticeable physiological strain.

Quick Fact: Relief for Inflammation
Ibufen supports patients by easing inflammatory symptoms like swelling and joint stiffness, which may assist with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ibufen — official regulatory information

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label) Adults and adolescents are the standard approved population. Pediatric patients over 6 months of age are generally permitted, typically using liquid formulations.
Populations for whom use is not recommended (if applicable) Use is not recommended in infants under 6 months of age as safety and efficacy are not established. Use is avoided in pregnancy starting at 20 weeks gestation and later, unless specifically advised by a healthcare professional.
Populations for whom use is contraindicated Patients with known hypersensitivity to Ibufen, aspirin, or other NSAIDs (e.g., history of allergic reactions or asthma). Individuals undergoing or immediately following Coronary Artery Bypass Graft (CABG) surgery. Patients with active gastrointestinal ulceration, bleeding, or perforation. Patients with severe heart failure or severe renal/hepatic impairment.
Age-related eligibility rules Older adults (typically over 65 years) must use the lowest effective dose for the shortest duration due to increased risk. The pediatric minimum age is generally 6 months, though this varies by specific product formulation.
Condition-specific eligibility rules The medicine is contraindicated in conditions such as severe heart failure and severe organ impairment. It requires restricted use in those with pre-existing cardiovascular risk factors (e.g., hypertension) or a history of GI disease (e.g., ulcerative colitis).
Pregnancy and lactation eligibility status (if explicitly documented) Pregnancy: Contraindicated from 20 weeks gestation onward; Lactation: Use of the lowest effective dose for short-term pain relief is generally considered compatible.

Eligibility Classifications (High-Level)

Classification Description
Eligibility severity classification (as defined in official documents) Contraindicated (absolute prohibition); Not Recommended (use avoided); Use with Caution (conditional use with monitoring).
Regulatory basis (EMA / FDA / etc.) The eligibility profile is based on the established safety and efficacy data for the entire Nonsteroidal Anti-Inflammatory Drug (NSAID) pharmacological class.

Connection to the overall eligibility profile: Regulatory documents strictly define who can and cannot use Ibufen by classifying certain pre-existing conditions (e.g., active GI bleeding, severe organ failure) and life stages (e.g., late pregnancy) as absolute contraindications. The profile restricts use in other vulnerable groups, such as those with mild organ impairment or advanced age, by mandating conditional use protocols, thereby establishing a formal eligibility boundary based solely on patient population characteristics.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ibufen, containing Ibuprofen, has several officially documented interaction patterns based on regulatory labeling. Co-administration is contraindicated with other nonsteroidal anti-inflammatory drugs (NSAIDs), including COX-2 selective inhibitors, due to an increased risk of severe gastrointestinal (GI) adverse events, such as ulceration and bleeding.

Pharmacodynamic and Clearance Interactions

Interactions are generally classified as either pharmacodynamic (additive effects) or affecting clearance. Co-administration with anticoagulants (e.g., Warfarin) and antiplatelet agents significantly increases the documented risk of haemorrhagic complications and GI bleeding. Ibufen may also reduce the antihypertensive effect of diuretics and ACE inhibitors, while increasing the risk of nephrotoxicity.

Separately, Ibufen reduces the renal clearance of medicines like Lithium and high-dose Methotrexate, leading to increased plasma concentrations of these co-administered drugs. The consumption of alcohol is also documented to increase the risk of serious GI bleeding.

Timing-Based Administration Rule

To prevent the attenuation of low-dose, immediate-release Aspirin's antiplatelet effect, a mandatory separation window is specified in regulatory information. Ibufen must be taken at least 30 minutes after or at least 8 hours before the aspirin dose. Elderly patients face a higher risk for increased severity across these documented adverse interaction outcomes.

Mechanism of Action

Primary Mechanism: Inhibiting Cyclooxygenase (COX) Enzymes

Ibufen's core action is rooted in its non-selective inhibition of the Cyclooxygenase (COX) enzyme isoforms (COX-1 and COX-2). This enzyme-mediated action directly targets the initial molecular steps required to synthesize lipid mediators, modulating the chemical sequences that relay signaling related to inflammation and pain.


Modulating the Prostaglandin Synthesis Pathway

By blocking COX enzyme activity, Ibufen suppresses the subsequent prostaglandin synthesis pathway. This mechanistic domain involves reducing the overall concentration of key mediators that dominate pain and inflammation responses. This alteration of signaling dynamics modulates heightened physiological activity.


Resulting Physiological Attenuation of Signaling Cascades

The reduction of these mediators leads to an attenuation of central and peripheral signaling cascades. This mechanism contributes to an altered state of signaling within targeted pathways, ultimately resulting in measurable physiological adjustments.

Dosage and Administration Information

The administration of Ibufen is defined by official delivery methods, dose parameters, and scheduling rules. The primary delivery method is the oral route, encompassing tablets, capsules, and suspensions, with an intravenous (IV) solution reserved for use in supervised clinical settings.

Dosing is guided by whether the product is used over-the-counter or by prescription. The typical adult dose for general pain and fever starts between 200 mg to 400 mg per administration. Established parameters include a maximum daily intake of 1200 mg for non-prescription use, while prescribed regimens may allow up to 3200 mg daily in divided doses. The standard frequency pattern requires administration every 4 to 6 hours as needed, ensuring a minimum time interval is observed between doses.

Usage constraints emphasize the procedural principle of using the lowest effective dose for the shortest duration necessary to meet treatment goals. Practical instructions state that the medicine may be administered with food or milk to help reduce gastrointestinal complaints. For the pediatric population, dosing is determined based on the child's body weight (typically 5 mg/kg to 10 mg/kg per dose) and is not to exceed a maximum of 40 mg/kg per day. Specific liquid forms must be shaken well prior to administration to ensure accurate dosing.

Recent Clinical Evidence

Ibuprofen, the active component of Ibufen, is supported by clinical research studies, primarily using short-term Randomized Controlled Trials (RCTs) and meta-analyses. Research exploring the use of Ibufen for outcomes related to acute pain (e.g., headache and dental pain) and fever reduction relies on trials conducted during periods of increased symptom activity. These studies monitored patient-reported outcomes and documented patterns in the reporting of pain scores and temperature changes within the first few hours following a dose.

Ibufen was also studied for its role in conditions involving periods of heightened symptoms, such as arthritis and primary dysmenorrhea (menstrual cramping). For these conditions, medium-to-long-term RCTs and extended observational studies examined outcomes related to daily functioning and symptom intensity. The findings document group patterns in symptom scores monitored over weeks or months, contributing to the broader evidence landscape.

Research has also explored the long-term use of Ibufen, especially in observational settings for arthritis. Evidence is limited regarding the durability of symptomatic response after treatment ceases, and the data describe use patterns over time rather than providing definitive evidence about the clinical impact on disease modification. Comparative evidence is lacking regarding long-term, direct comparisons with all other NSAID options.

Ibufen was evaluated in studies involving specific age groups, most notably pediatric patients for the management of acute pain and fever. However, data for certain groups, such as older adults with specific comorbidities, are still emerging or remain insufficient for broad conclusions. Research provides context regarding short-term symptom patterns but does not determine whether an individual will respond similarly to the group patterns observed.

Key Studies & References Systematic Review on Treatments for Acute Pain: Surveillance Report 1

Frequently Asked Questions (FAQ)

Common questions about Ibufen (FAQ)

Q: Is Ibufen the same as standard over-the-counter pain relievers?

A: Official information classifies Ibufen’s active ingredient, Ibuprofen, as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This is a specific pharmacological class that works by reducing inflammation. Other common over-the-counter pain relievers, such as acetaminophen, belong to a different class of medicine and act via different mechanisms.

Q: What is the main difference between Ibufen and Acetaminophen?

A: Ibufen is an NSAID that acts by inhibiting COX enzymes, which reduces the production of chemical mediators responsible for inflammation, pain, and fever. Acetaminophen, in contrast, is not generally considered an anti-inflammatory medicine and works primarily to relieve pain and reduce fever through mechanisms that are distinct from the COX enzyme inhibition.

Q: What if I forget a dose of Ibufen? (Informational, not instruction-seeking)

A: Regulatory documents indicate that resuming the schedule at the next designated time is generally advised, ensuring the minimum specified time interval between administrations is met. It is explicitly noted that patients should not take extra medicine to make up for the forgotten dose.

Q: Why does Ibufen sometimes make me feel sleepy?

A: Official documentation lists somnolence, which refers to drowsiness or sleepiness, as an adverse reaction that may occur. This is categorized as a nervous system disorder and is listed among the known, though less common, side effects. The occurrence and severity of this reaction vary among patients.

Q: Is it normal to feel dizzy after taking Ibufen?

A: Dizziness is documented in official product information as a known adverse reaction to the medicine. It is typically classified among the common or uncommon side effects, depending on the specific product formulation. If this effect occurs, regulatory documents suggest exercising caution.

Q: Can Ibufen affect my ability to drive or operate machinery?

A: Regulatory documents advise that if certain adverse effects like dizziness, vertigo, or visual disturbances are experienced, an individual's ability to concentrate or react may be impaired. These documents suggest exercising caution when performing activities that require alertness, such as driving or operating heavy machinery.

Q: Is Ibufen generally taken at a specific time of day?

A: Official guidance emphasizes that Ibufen should be taken as needed every 4 to 6 hours, regardless of the time of day, provided the minimum time interval between doses is observed. The medicine is often suggested to be administered with food or milk, which may help reduce the chance of gastrointestinal complaints.

Q: How long does Ibufen stay in my system after the last dose?

A: Official pharmacokinetics data documents the half-life of Ibufen (Ibuprofen) to be approximately 1.8 to 2.2 hours. Based on this elimination rate, the drug’s active component is expected to be almost completely eliminated from the body within roughly 10 to 24 hours after the final dose.

Q: Does Ibufen interact with common vitamins like Vitamin D or C?

A: Official drug interaction lists for Ibufen focus on specific categories of drugs, such as blood thinners and other NSAIDs. Vitamins C and D are generally not listed in regulatory documents as having clinically significant pharmacokinetic interactions that would require a change in Ibufen dosing or administration.

Q: What is Ibufen actually used for, besides what the TV ads show?

A: According to official regulatory indications, Ibufen is approved for the temporary relief of mild to moderate pain and the reduction of fever. It is also used to treat inflammation associated with specific conditions such as arthritis, primary dysmenorrhea (menstrual pain), and common headaches.

Q: Why is Ibufen sometimes prescribed and sometimes available without a prescription?

A: The medicine's status as either prescription (Rx) or over-the-counter (OTC) depends on its dosage strength and the maximum permitted total daily dose. Lower strengths and restricted daily maximums are approved for OTC sale, while higher strengths and maximum daily doses are reserved for prescription use, reflecting the officially documented increased potential risks at higher exposures.

Q: How quickly should Ibufen start to work?

A: Studies and official pharmacodynamics information indicate that the onset of pain-relieving action typically begins within 20 to 30 minutes following administration of an oral dose. The maximum pain relief effects are often observed within 1 to 2 hours.

Q: What is the typical length of time Ibufen's effects last?

A: Official information derived from clinical studies indicates that the pain-relieving effects of a single dose of Ibufen generally last for approximately 4 to 6 hours. This timeframe aligns with the standard minimum time interval designated for administrations.

Q: Can Ibufen be taken by people with kidney issues?

A: Regulatory documents state that Ibufen is contraindicated (should not be used) in patients with severe renal impairment or severely impaired/deteriorating kidney function. For individuals with less severe kidney issues, regulatory documents note that use is conditional and should be managed with caution due to the potential for kidney function changes.

Q: Is Ibufen appropriate for use in children?

A: Ibufen is officially approved and indicated for use in pediatric patients who are typically over 6 months of age, most often administered using specific liquid formulations. Use in infants under 6 months is generally avoided because safety and efficacy data are not established for that age group.

Q: Are there any common foods or drinks that interact with Ibufen?

A: The most notable interaction documented in regulatory safety warnings is with alcohol consumption, which is explicitly noted to increase the risk of serious gastrointestinal bleeding. The medicine may be taken with food or milk, which may help reduce common stomach complaints.

Q: What is the risk of Ibufen causing stomach upset?

A: Official documentation classifies gastrointestinal issues such as nausea, vomiting, and indigestion as Common adverse reactions. In addition to these upsets, regulatory warnings also highlight the serious, dose-related risks of gastrointestinal bleeding, ulceration, and perforation.

Q: How long do most people take Ibufen before switching to something else?

A: Regulatory guidelines emphasize using the lowest effective dose for the shortest duration necessary to achieve treatment goals. For non-prescription use, package labeling typically restricts continuous use to a few days (e.g., 3 days for fever, 10 days for pain) unless otherwise directed by a healthcare professional.

Q: Is Ibufen considered a long-term treatment option?

A: Ibufen is primarily studied and indicated for short-term use. While it may be used long-term under prescription for chronic conditions like certain types of arthritis, regulatory safety warnings state that the risk of serious side effects, particularly cardiovascular and gastrointestinal events, increases with higher doses and longer duration of use.

Q: What kind of research has been done on the long-term use of Ibufen?

A: The long-term use of Ibufen has primarily been examined in extended observational studies focusing on use patterns in chronic conditions such as arthritis. Official evidence indicates that data is limited regarding the durability of symptomatic response after treatment ceases, and robust comparative long-term evidence is often lacking.

Q: Is Ibufen known to cause any skin reactions or rashes?

A: Yes, official documentation lists skin reactions such as rash and pruritus (itching) as uncommon adverse reactions. Furthermore, regulatory warnings highlight the potential for rare but serious, sometimes fatal, skin reactions, including conditions like Stevens-Johnson Syndrome.

Q: Is Ibufen available in different forms, like liquid or chewable tablets?

A: The active ingredient of Ibufen is manufactured in various systemic dosage forms. These commonly include the tablet, capsule, liquid gel, oral suspension (liquid), and the suppository.

Q: Do studies support Ibufen's use for treating inflammation?

A: Ibufen is officially classified as an anti-inflammatory agent and is supported by research. Studies have examined and documented its use for reducing inflammation associated with conditions such as arthritis and primary dysmenorrhea. Its core mechanism of inhibiting prostaglandins directly addresses the biochemical processes of inflammation.

Q: Can Ibufen be used by elderly patients?

A: Older adults, typically defined as those over 65 years, are permitted to use Ibufen. However, regulatory guidance emphasizes using the lowest effective dose for the shortest duration due to the officially documented increased risk of adverse outcomes, especially gastrointestinal and cardiovascular events.

Q: Why do doctors often mention the liver when talking about Ibufen?

A: The liver is critical because Ibufen is extensively metabolized (processed) by the body via liver enzymes before it is eliminated. Because of this, severe liver failure (hepatic impairment) is listed as an absolute contraindication for use in regulatory documents.

Q: Is Ibufen commonly used for headaches or migraines?

A: Ibufen is officially indicated for the relief of mild to moderate pain, and research has documented its effectiveness for acute pain, which includes headaches. While it is widely used for headaches, migraine is a distinct and specific clinical category, and it is not universally listed as an approved indication on all regulatory labels.

Q: Does Ibufen have a known potential for dependence?

A: Regulatory agencies do not classify Ibufen as a controlled substance. The medicine is generally not associated with the physical dependence or abuse potential that is commonly documented with other classes of pain relievers, such as opioid analgesics.

Q: How does the effectiveness of Ibufen compare between different formulations?

A: Regulatory documents and bioequivalence studies indicate that some fast-acting formulations (e.g., liquid-gels) may show a faster onset of action—meaning they start relieving pain sooner—than standard tablets. However, the overall therapeutic effectiveness and the peak pain relief over the standard dosing interval is described as generally comparable.

Q: Can Ibufen be used for pain relief after a minor surgery?

A: Ibufen is officially indicated for the treatment of mild to moderate pain. While its use is contraindicated immediately following certain major procedures, regulatory documents permit its use in appropriate populations for short-term pain relief.

Q: Is Ibufen available generically?

A: Yes, Ibufen’s active ingredient, Ibuprofen, is an established compound that has been widely authorized. It is available through numerous generic formulations across various international markets, all of which are subject to regulatory standards for quality and bioequivalence.

Q: What is the background research supporting the use of Ibufen in children?

A: The research supporting pediatric use primarily involves short-term Randomized Controlled Trials (RCTs). These studies evaluated the drug's effectiveness and monitored outcomes related to the management of acute pain and fever reduction in children, particularly those over 6 months of age.

Q: How do the studies define the 'onset of action' for Ibufen?

A: Regulatory documents describe that the onset of action is typically determined by research protocols that involve monitoring patient-reported outcomes. This includes documenting patterns and changes in symptom intensity, such as pain scores, during the first few hours following the administration of a dose.

How should Ibufen be stored and disposed of?

The storage and disposal of Ibufen (Ibuprofen) must strictly follow the conditions defined in official regulatory documents to ensure stability and safety.

Storage and Handling

Ibufen must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must avoid excessive heat above 40 C and must not be frozen. To maintain its labeled shelf life, store the medicine in a tightly closed, original container, and protect it from moisture and light.

Disposal and Safety

The medicine must always be kept out of the sight and reach of children. Unused or expired Ibufen should be disposed of in accordance with local regulations for medicinal waste. It is explicitly instructed not to throw the product away via wastewater or household trash where pharmaceutical take-back programs are available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ibufen found in:

A-Z Index: